Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus chemotherapy for 2 versus 3 cycles before surgery in locally advanced esophageal squamous cell carcinoma
ChiCTR2500098521Phase 4Not yet recruiting
- Sponsor
- Jining First People's Hospital
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of toripalimab and PD-1 Monoclonal Antibody in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal cancer (2 arms), sponsored by Jining First People's Hospital. Primary endpoint: pathological complete response and major pathological response rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
toripalimabPD-1 Monoclonal Antibody
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR2500098521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098521.